As to phase II trials, in the MD Anderson Hospital study22 two sequential CD20+ BCP ALL patient cohorts receiving Hyper-CVAD chemotherapy with or without rituximab were analyzed. The gene discussed is MS4A1; the disease is acute lymphoblastic leukemia.